The development of drugs to treat acute stroke or aid in stroke recovery is an endeavor that only rarely pays off in the form of approval. Drug companies spend years testing safety and dosage in the clinic, only to find in Phase 3 clinical efficacy trials have little to no benefit. A robot developed at MIT may help speed up drug development, letting companies know earlier in the process whether a drug will work in stroke patients.
The drugmaker working to develop a pill to boost sexual desire in women says regulators are demanding more studies on the experimental drug. Sprout Pharmaceuticals said that the Food and Drug Administration wants to see more data on how the company's drug, flibanserin, interacts with other medications and how it affects driving ability. Nearly 10 percent of women studied in company trials reported sleepiness while taking the daily pill.
Some of the world's biggest drugmakers are playing a larger role in anti-doping efforts at this year's Winter Olympics: They're providing information on drugs that once would have been considered proprietary trade secrets. GlaxoSmithKline, Amgen, and Roche are among the drugmakers that have begun sharing "confidential research and data" with anti-doping officials about experimental drugs they are developing.
Scientists at UCSD developed a new genetic platform that allows efficient production of naturally occurring molecules, and have used it to produce a novel antibiotic compound. The scientists harvested a set of genes predicted to encode a natural product from ocean bacteria, then used synthetic biology technology to identify and test a new antibiotic – taromycin A – found to be effective in fighting drug-resistant MRSA.
Johnson & Johnson has been offered $4.15 billion by The Carlyle Group for its Ortho-Clinical Diagnostics business, a year after J&J began reviewing strategic options for the blood-testing unit as part of a routine pruning of its extensive family of businesses. J&J has until March 31 to decide whether to accept the offer.
Biotech drugmaker Amgen and Illumina, a maker of genetic testing equipment, said Wednesday they are developing a test that will identify patients who might be helped by Amgen's colon cancer drug Vectibix. Vectibix is approved as a treatment for colorectal cancer that has spread and hasn't rresponded to chemotherapy.
Researchers at the University of Cincinnati (UC) have identified key molecular components linking circadian rhythms and cell division cycles in Neurospora crassa, providing insights that could lead to improved disease treatments and drug delivery.
Talk about mind over matter: A quirky new study suggests patients' expectations can make a big difference in how they feel after treatment for a migraine.
Engineers hope a new type of vaccine they have shown to work in mice will one day make it cheaper and easy to manufacture on-demand vaccines for humans. Immunizations could be administered within minutes where and when a disease is breaking out.
The Food and Drug Administration approved 27 first-of-a-kind drugs in 2013, down from 39 new medications in 2012, which was a 15-year high.
Scientists have revealed an atomic-level view of a genetic defect that causes a form of muscular dystrophy, myotonic dystrophy type 2, and have used this information to design drug candidates with potential to counter those defects.
Biologists at The Johns Hopkins University have discovered that low oxygen conditions, which often persist inside tumors, are sufficient to initiate a molecular chain of events that transforms breast cancer cells from being rigid and stationery to mobile and invasive.
Scientists have obtained the first detailed molecular structure of a member of the Tet family of enzymes. The finding is important for the field of epigenetics because Tet enzymes chemically modify DNA, changing signposts that tell the cell's machinery "this gene is shut off" into other signs that say "ready for a change."
A team of researchers from Canada has developed a class of compounds which may help eradicate a neglected tropical disease that is currently hard to kill in its chronic form. The research was published ahead of print in Antimicrobial Agents and Chemotherapy.
Scientists at The Scripps Research Institute (TSRI) have demonstrated a drug-discovery strategy with a double payoff—it enables the rapid selection of chemical compounds that have a desired effect on cells and also highlights how the compounds work. To illustrate the power of the innovative technique, the TSRI researchers used it to identify a compound that shows promise for treating obesity-linked diabetes. Learn more...
Researchers have identified how the ‘wall’ around cancer tumors functions and how to break it down, enabling the body’s own defenses to reach and kill the cancer cells within.
Researchers report promising steps toward the creation of a universal flu vaccine, one that could be produced more quickly and offer broader protection than the virus-specific inoculants available today.
Can an experimental drug developed to treat epilepsy block the AIDS virus? A preliminary lab study suggests it's possible, and researchers are eager to try it in people.
New recommendations for using X-rays promise to speed investigations aimed at understanding the structure and function of biologically important proteins– information critical to the development of new drugs.
In a new study researchers have found a way of reducing ALS disease toxicity, which slows the dysfunction of neurons and shows that a parallel mechanism can reduce toxicity in mammalian cells.
There's more disappointing news about multivitamins: Two major studies found popping the pills didn't protect aging men's brains or help heart attack survivors.
Scientists have discovered a key process during the invasion of the blood cell by the Malaria parasite, and more importantly, found a way to block this invasion.
A novel way to speed the testing of cancer drugs and quickly separate winners from duds has yielded its first big result: an experimental medicine that shows promise against a hard-to-treat form of breast cancer.
Widely used treatments for type 2 diabetes have different effects on the hearts of men and women, even as the drugs control blood sugar equally well in both sexes, according to new research.